NCT00017238View on ClinicalTrials.gov

KRN5500 in Treating Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

November 30, 2008

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

KRN5500

Given IV

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00017238 - KRN5500 in Treating Patients With Solid Tumors | Biotech Hunter | Biotech Hunter